Ero sivun ”Rituksimabi” versioiden välillä
| [katsottu versio] | [katsottu versio] |
Poistettu sisältö Lisätty sisältö
Rivi 5:
Rituksimabin kehitti [[Biogen Idec|IDEC Pharmaceuticals]] tuotenimellä '''IDEC-C2B8'''.<ref>[http://www.sandiegometro.com/1999/apr/biotech.html "Why San Diego Has Biotech"], Fikes, Bradley J. ''San Diego Metropolitan,'' April 1999. Accessed June 20, 2008.</ref>
Perustuen [[Kliininen tutkimus| kliinisiin tutkimuksiin]],<ref>{{cite journal |author=Maloney DG, Grillo-López AJ, White CA, ''et al.'' |title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma |journal=Blood |volume=90 |issue=6 |pages=2188–95 |year=1997 |month=September |pmid=9310469 |doi= |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469}}</ref> rituksimabi sai hyväksynnän USA:n [[FDA]]:lta vuonna 1997.<ref>{{cite journal |author=Scott SD |title=Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma |journal=Cancer Pract |volume=6 |issue=3 |pages=195–7 |year=1998 |pmid=9652253 |doi= 10.1046/j.1523-5394.1998.006003195.x|url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1065-4704&date=1998&volume=6&issue=3&spage=195}}</ref>
Rituximab is currently co-marketed by [[Biogen Idec]] and [[Genentech]] in the U.S., by [[Hoffmann–La Roche]] in Canada and the [[European Union]], and by [[Chugai Pharmaceuticals]] and Zenyaku Kogyo in Japan.
| |||